At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
Vupanorsen +1 moredrug
Likely dose
Vupanorsen 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, RANDOMIZED, OPEN-LABEL, SINGLE DOSE STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF VUPANORSEN ADMINISTERED SUBCUTANEOUSLY TO HEALTHY CHINESE ADULTS
In Brief
A Phase 1 clinical trial evaluating Vupanorsen for Healthy. Completed, enrolled 18 participants across 1 site.
Detailed Summary
This is a Phase 1, randomized, parallel-cohort, open-label study to characterize the pharmacokinetics, pharmacodynamics, safety and tolerability of vupanorsen following 80 mg and 160 mg single subcutaneous dose in healthy Chinese adults with elevated fasting triglyceride.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartJun 2021
Primary CompletionOct 2021
TodayJul 2026
First PostedJun 8, 2021
Enrollment StartJun 17, 2021
Primary CompletionOct 19, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.1 years ago
Interventions
Vupanorsendrug
80 mg subcutaneous injection
Vupanorsendrug
80 mg subcutaneous injection